Back to top
more

Immune Design Corp. (IMDZ)

(Delayed Data from NSDQ)

$5.85 USD

5.85
NA

0.00 (0.00%)

Updated Apr 1, 2019 04:00 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy23.68%
2Buy17.55%
3Hold9.21%
4Sell4.93%
5Strong Sell2.36%
S&P50010.96%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

NA Value NA Growth NA Momentum NA VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

NA

Industry: NA

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Better trading starts here.

Zacks News

The Zacks Analyst Blog Highlights: Merck, Design, Roche and AbbVie

by Zacks Equity Research

The Zacks Analyst Blog Highlights: Merck, Design, Roche and AbbVie

Merck to Buy Immunotherapy Developer Immune Design for $300M

by Zacks Equity Research

Merck (MRK) plans to acquire Immune Design for $300 million in cash. Merck will pay $5.85 in cash for each share of Immune Design.

Pharma Stock Roundup: MRK Buys IMDZ, FDA Grants Priority Review to Some Candidates

by Zacks Equity Research

Merck (MRK) to buy Immune Design for $300 million. FDA grants priority review to regulatory applications filed by Merck, Roche (RHHBY) and AbbVie (ABBV).

Why Is Immune Design (IMDZ) Up 15.8% Since Last Earnings Report?

by Zacks Equity Research

Immune Design (IMDZ) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

Immune Design (IMDZ) Posts Narrower-Than-Expected Loss in Q3

by Zacks Equity Research

Immune Design (IMDZ) posts narrower-than-expected loss and misses revenue estimates in the third quarter of 2018. It expects to have cash to fund operations in 2021.

Immune Design (IMDZ) Reports Q3 Loss, Lags Revenue Estimates

by Zacks Equity Research

Immune Design (IMDZ) delivered earnings and revenue surprises of 9.38% and -37.99%, respectively, for the quarter ended September 2018. Do the numbers hold clues to what lies ahead for the stock?

Immune Design to Halt Cancer Vaccine Program, Shares Plunge

by Zacks Equity Research

Immune Design (IMDZ) to discontinue the CMB305 cancer vaccine program and focus on the development of its lymphoma therapy, G100.

Implied Volatility Surging for Immune Design (IMDZ) Stock Options

by Zacks Equity Research

Investors need to pay close attention to Immune Design (IMDZ) stock based on the movements in the options market lately.

    Immune Design (IMDZ) Down 2.8% Since Last Earnings Report: Can It Rebound?

    by Zacks Equity Research

    Immune Design (IMDZ) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

      Immune Design (IMDZ) Posts Narrower-Than-Expected Loss in Q2

      by Zacks Equity Research

      Immune Design (IMDZ) reports narrower-than-expected loss and beats revenue estimates in the second quarter of 2018.

        Immune Design (IMDZ) Reports Q2 Loss, Tops Revenue Estimates

        by Zacks Equity Research

        Immune Design (IMDZ) delivered earnings and revenue surprises of 3.33% and 17.97%, respectively, for the quarter ended June 2018. Do the numbers hold clues to what lies ahead for the stock?

          What's in Store for Immune Design (IMDZ) in Q2 Earnings?

          by Zacks Equity Research

          We expect Immune Design (IMDZ) to focus on the progress of its pipeline candidates in the second quarter earnings call.

            Immune Design (IMDZ) Posts Narrower-Than-Expected Loss in Q1

            by Zacks Equity Research

            Immune Design (IMDZ) posts narrower-than-expected loss and misses revenue estimates in Q1. The company remains on track to start a pivotal phase III study for CMB305 on patients with synovial sarcoma.

              What's in the Cards for Immune Design (IMDZ) in Q1 Earnings?

              by Zacks Equity Research

              During the earnings call, we expect Immune Design to shed light on the progress of its pipeline candidates-CMB305 and G100 .

                Why Is Immune Design (IMDZ) Down 2.7% Since Its Last Earnings Report?

                by Zacks Equity Research

                Immune Design (IMDZ) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

                  Immune Design Poised on Progress of Pipeline Candidates

                  by Zacks Equity Research

                  Development of key pipeline candidates CMB305 and G100 is likely to keep Immune Design (IMDZ) on a growth trajectory.

                    Immune Design (IMDZ) Posts Narrower-Than-Expected Loss in Q4

                    by Zacks Equity Research

                    Immune Design (IMDZ) reports narrower-than-expected loss in fourth quarter 2017 results and updates data for its pipeline candidates.

                      What's in the Cards for Immune Design (IMDZ) in Q4 Earnings?

                      by Zacks Equity Research

                      We expect Immune Design (IMDZ) to shed light on the progression of the trails on pipeline candidates when it releases fourth-quarter earnings results on Mar 6.

                        Why Immune Design (IMDZ) Could Beat Earnings Estimates Again

                        by Zacks Equity Research

                        Immune Design (IMDZ) boasts a favorable Zacks Rank and a positive Earnings ESP, which is a great sign of a coming earnings beat.

                          Options Traders Expect Huge Moves in Immune Design (IMDZ) Stock

                          by Zacks Equity Research

                          Immune Design (IMDZ) needs investors to pay close attention to the stock based on moves in the options market lately.

                            Options Traders Expect Huge Moves in Immune Design (IMDZ) Stock

                            by Zacks Equity Research

                            Investors in Immune Design (IMDZ) need to pay close attention to the stock based on moves in the options market lately.

                              Immune Design (IMDZ) Posts Narrower-than-Expected Loss in Q3

                              by Zacks Equity Research

                              Immune Design (IMDZ) reported narrower-than-expected loss and missed sales estimates in the third-quarter 2017.

                                What's in the Cards for Immune Design (IMDZ) in Q3 Earnings?

                                by Zacks Equity Research

                                Immune Design (IMDZ) will remain focused on the development of its key pipeline candidate's CMB305 and G100 in the third quarter of 2017.

                                  Options Traders Expect Huge Moves in Immune Design (IMDZ) Stock

                                  by Zacks Equity Research

                                  Investors in Immune Design (IMDZ) need to pay close attention to the stock based on moves in the options market lately.

                                    Immune Design's Sarcoma Candidate to Enter Phase III in 2018

                                    by Zacks Equity Research

                                    Immune Design (IMDZ) plans to initiate a pivotal phase III study to support a Biologics License Application (BLA) for CMB305.